Valuation: Shanghai Rightongene Biotechnology Co., Ltd.

Market Cap 1.33B 199M 178M 166M 150M 283M 18.92B 285M 1.99B 778M 9.84B 749M 732M 31.58B P/E 2024
-65.9x
P/E 2025 -29x
Enterprise Value 1.11B 166M 148M 138M 125M 236M 15.77B 238M 1.66B 649M 8.2B 624M 610M 26.32B EV / Sales 2024
3.33x
EV / Sales 2025 6.95x
Free-Float
62.32%
Yield 2024 *
-
Yield 2025 0.65%
08-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
04-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
16/10/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
08/09/25 Shanghai Rightongene Biotechnology's boards elects chairman RE
28/08/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
24/04/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
27/02/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25/02/25 Shanghai Rightongene Biotechnology Receives 1.8 Million Yuan in Government Subsidies MT
20/02/25 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
18/02/25 Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback announced on February 29, 2024, has closed with 669,621 shares, representing 1.2% for CNY 17.02 million. CI
03/01/25 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
29/10/24 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
1 week-5.73%
Current month-5.73%
1 month+4.31%
3 months+13.15%
6 months-12.30%
Current year-8.24%
1 week 22.83
Extreme 22.83
27
1 month 22.38
Extreme 22.38
27
Current year 17.81
Extreme 17.81
33.27
1 year 17.81
Extreme 17.81
33.27
3 years 12.38
Extreme 12.38
43.05
5 years 12.38
Extreme 12.38
86.39
10 years 12.38
Extreme 12.38
133.67
Manager TitleAgeSince
Chief Executive Officer 69 22/07/2024
Director of Finance/CFO 34 27/01/2025
Investor Relations Contact - -
Director TitleAgeSince
Chairman 69 22/07/2024
Director/Board Member 41 13/05/2019
Director/Board Member 53 24/08/2023
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-5.73%-14.80%-36.08% 199M
-0.68%+3.87%-23.05%+11.25% 178B
-0.66%+8.08%-4.27%+28.81% 119B
-0.76%+1.96%-24.11%+6.33% 108B
+0.79%+0.55%-45.83%-10.97% 75.27B
+0.98%+5.24%+5.01%+78.67% 62.99B
+0.34%+1.05%+19.75%+67.00% 53.46B
-0.28%+3.96%-0.57%-27.89% 51.04B
+1.06%+3.99%-17.28%+22.66% 40.99B
-0.78%+0.93%+28.50%+7.76% 32.1B
Average +0.02%+1.70%-7.66%+14.75% 72.1B
Weighted average by Cap. -0.16%+3.15%-12.64%+18.82%

Financials

2024 2025
Net sales 242M 36.2M 32.34M 30.14M 27.33M 51.43M 3.44B 51.83M 361M 141M 1.79B 136M 133M 5.73B 177M 26.48M 23.66M 22.05M 19.99M 37.62M 2.51B 37.92M 264M 103M 1.31B 99.45M 97.27M 4.2B
Net income -15.76M -2.36M -2.1M -1.96M -1.78M -3.35M -224M -3.37M -23.49M -9.2M -116M -8.84M -8.65M -373M -50.38M -7.53M -6.72M -6.27M -5.68M -10.69M -714M -10.78M -75.07M -29.39M -372M -28.26M -27.64M -1.19B
Net Debt -210M -31.42M -28.07M -26.16M -23.72M -44.63M -2.98B -44.98M -313M -123M -1.55B -118M -115M -4.98B -222M -33.23M -29.69M -27.67M -25.09M -47.21M -3.15B -47.58M -331M -130M -1.64B -125M -122M -5.26B
Projected Income Statement - Annual - Shanghai Rightongene Biotechnology Co., Ltd.
Logo Shanghai Rightongene Biotechnology Co., Ltd.
Shanghai Rightongene Biotechnology Co Ltd is a China-based company mainly engaged in the research and development, production, sales, scientific research, and testing services of in vitro diagnostic products. The Company mainly provides self-branded molecular diagnostic reagents, scientific research services, testing services, and molecular testing equipment. The Company's main products are molecular diagnostic kits for leukemia, lymphoma, solid tumors, and infectious disease related genes. The Company's main services include providing third-party medical testing services for various medical institutions, pharmaceutical companies, individual patients, and others, as well as providing genetic testing research services for research hospitals, pharmaceutical companies, scientific research institutions, third-party testing institutions and other enterprises and institutions.
Employees
327
Date Price Change Volume
13/10/26 CN¥24.18 0.00% 1,374,263
12/10/26 CN¥24.18 -2.62% 1,119,922
09/10/26 CN¥24.83 -1.62% 1,519,437

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Shanghai Rightongene Biotechnology Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 688217 Stock